Clinical Trial Update: Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration [Phase 1, Phase 2]

View source ↗

Summary

Phase I/IIA trial of SAR422459 for Stargardt's disease was terminated with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stargardt Disease

Drugs mentioned

• SAR422459

Snippet

Sponsor: Sanofi | Conditions: Stargardt's Disease | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-06-05